NEXTCURE APPOINTS KEVIN N. HELLER, M.D., AS CHIEF MEDICAL OFFICER AND STEVE COBOURN, CPA, AS CHIEF FINANCIAL OFFICER
BELTSVILLE, MD, April 4, 2018 – NextCure, Inc. today announced the appointment of Kevin N. Heller, M.D., as Chief Medical Officer and Steve Cobourn, CPA, as Chief Financial Officer.
“We are delighted to welcome Kevin and Steve to NextCure,” stated Michael Richman, NextCure’s President & CEO. “Both are accomplished executives with proven track records in building biopharmaceutical companies.”
“Kevin’s experience in clinical development of novel immune checkpoint therapeutics will provide great value to NextCure as we enter the clinic later this year with NC318, a first-in-class candidate,” added Mr. Richman. “Steve brings significant expertise in financial management of biopharmaceutical companies and his leadership will be invaluble to NextCure.”
Most recently Dr. Heller was Vice President, Head of mAb Clinical Development, Immuno-Oncology at Incyte Corporation where he led the clinical development of Incyte’s monoclonal antibody programs for cancer immunotherapy. He was also Chair of Incyte’s Immunotherapy Strategy Team. Prior to joining Incyte, Dr. Heller was the Senior Medical Director for Oncology at AstraZeneca where he led late stage clinical development programs. Dr. Heller also held various positions at Bristol-Myers Squibb (BMS) where he was Director, US Medical Lead for Ipilimumab and Global Lead, Oncology, Strategic Transactions Group . He received his M.D. from George Washington University and B.S. in Molecular Biophysics & Biochemistry from Yale University.
Mr. Cobourn has more than 20 years of experience in life sciences including financing, product launches, alliances, and operations. Previously, he was the Chief Financial Officer of Vaccinex, Inc., a privately held clinical-stage biotechnology company. Prior to joining Vaccinex, Mr. Cobourn was Vice President of Finance, Treasurer, and Corporate Officer of Otsuka America Pharmaceutical, Inc., the U.S. division of publicly traded Otsuka Holdings Co., Ltd. During his tenure, he participated in overseeing the growth of revenue from Otsuka’s U.S. operations from $10 million to $5 billion. He received his B.S. in Business Administration from Drexel University and is a Certified Public Accountant in the State of Pennsylvania.
About NextCure, Inc.
NextCure is a biopharmaceutical company focused on discovering and developing next generation first-in-class immunotherapy-based biologics for cancer and other diseases. The company leverages its FIND-IOTM technology to discover, validate and build a proprietary pipeline of novel imunotherapy targets.
NC318 is a first-in-class immunotherapeutic directed against a novel target found on myeloid cells and tumor cells. NC318 prevents the formation and survival of suppressive myeloid cells and blocks the suppressive function of macrophages, leading to increased T cell function and anti-tumor immunity. NextCure is initially moving NC318 forward for the treatment of solid cancers and plans to file an IND in 3Q 2018.
Please visit www.nextcure.com for more information.
Timothy Mayer, Ph.D.
VP, Business Operations & Administration
NextCure, Inc., New Immuno-Oncology Firm, Announces $67 Million Series A Financing
Jan 06, 2016, 06:00 ET
GERMANTOWN, Md. and NEW HAVEN, Conn., Jan. 6, 2016 /PRNewswire/ — NextCure, Inc., a newly formed biopharmaceutical company focused on the discovery and development of new immuno-oncology products, today announced that it has raised a $67 million Series A financing. Major investors in the financing Canaan Partners, Lilly Asia Ventures, OrbiMed Advisors, Pfizer Inc. and Sofinnova Ventures, were joined by Alexandria Venture Investments.
NextCure was founded in 2015 by Michael Richman, who will serve as its President and Chief Executive Officer, and Lieping Chen, M.D., Ph.D., United Technologies Endowed Professor of Cancer Research, Professor of Immunobiology, Dermatology, and Medicine at the Yale School of Medicine. The Company plans to develop product candidates licensed from Dr. Chen’s laboratory and has entered into a multi-year agreement with Yale University under which it will sponsor research and hire new scientists in Dr. Chen’s laboratory. In 2014, Dr. Chen received the William B. Coley Award for outstanding achievements in Basic and Tumor Immunology for his discovery of the PD-1/PD-L1 pathway as target for cancer immunotherapy. This pathway is targeted by two cancer immunotherapy drugs in current clinical use (Opdivo®, Keytruda®) and by many other products in clinical development.
“Immuno-oncology drugs are making a big impact on the survival of many cancer patients. Our research is targeted to finding new cures for those patients and tumor types which do not adequately respond to available therapy,” said Dr. Chen.
“The NextCure management team is honored to once again collaborate with Dr. Chen and we are gratified by the support of our Series A investors in funding our ambitious target discovery and product development plans,” said Mr. Richman. “The Company has begun recruiting scientists and will commence operations in the coming months.”
Mr. Richman was previously President and Chief Executive Officer of Amplimmune, Inc., a biologics company focused on cancer and autoimmune diseases that was acquired by AstraZeneca plc. Three other former members of the Amplimmune management team will join Mr. Richman on the NextCure management team: Solomon Langermann, Ph.D., who will serve as senior vice president of research; James Bingham, Ph.D., senior vice president of development and manufacturing and Linda Liu, Ph.D., vice president of translational research. David Kabakoff, Ph.D., executive partner of Sofinnova Ventures, who was a co-founder of and Chairman of Amplimmune, will serve as Chairman of NextCure. Dr. Chen was also a scientific co-founder of Amplimmune and inventor of key programs developed by the company.
About NextCure, Inc.
NextCure, launched in 2015, is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products. For more information, please visit www.nextcure.com.